Buys | $0 | 0 | 0 |
Sells | $36,521,689 | 25 | 100 |
Daly Richard J | President and CEO | 0 | $0 | 1 | $276,735 | $-276,735 |
Harper Molly | director | 0 | $0 | 2 | $471,949 | $-471,949 |
Tierney David S | director | 0 | $0 | 2 | $693,455 | $-693,455 |
Del Carmen Jeffrey | Chief Commercial Officer | 0 | $0 | 3 | $1.48M | $-1.48M |
Elsbernd Brian | Chief Compliance/Legal Officer | 0 | $0 | 3 | $2.14M | $-2.14M |
Miller Steve | Chief Op. & Scientific Officer | 0 | $0 | 2 | $4.15M | $-4.15M |
INGENITO GARY | Chief Med. & Reg. Officer | 0 | $0 | 6 | $9.07M | $-9.07M |
MCENANY PATRICK J | Chairman of Board of Directors | 0 | $0 | 6 | $18.23M | $-18.23M |
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular …
Over the last 12 months, insiders at Catalyst Pharmaceuticals, Inc. have bought $0 and sold $36.52M worth of Catalyst Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Catalyst Pharmaceuticals, Inc. have bought $130,960 and sold $17.44M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 30,000 shares for transaction amount of $89,100 was made by MCENANY PATRICK J (President and CEO) on 2020‑09‑30.
2025-03-06 | Sale | INGENITO GARY | Chief Med. & Reg. Officer | 180,096 0.1485% | $21.67 | $3.9M | -3.28% | |
2025-03-05 | Sale | INGENITO GARY | Chief Med. & Reg. Officer | 44,904 0.0371% | $22.09 | $991,929 | -3.74% | |
2025-03-03 | Sale | Elsbernd Brian | Chief Compliance/Legal Officer | 62,975 0.053% | $22.98 | $1.45M | -3.97% | |
2025-03-03 | Sale | Del Carmen Jeffrey | Chief Commercial Officer | 30,423 0.0255% | $22.89 | $696,382 | -3.97% | |
2024-12-10 | Sale | Miller Steve | Chief Op. & Scientific Officer | 50,000 0.0417% | $21.93 | $1.1M | -0.11% | |
2024-11-27 | Sale | INGENITO GARY | Chief Med. & Reg. Officer | 12,000 0.0102% | $22.72 | $272,654 | -1.32% | |
2024-11-27 | Sale | Harper Molly | director | 17,500 0.0144% | $22.00 | $385,000 | -1.32% | |
2024-11-26 | Sale | Elsbernd Brian | Chief Compliance/Legal Officer | 13,256 0.011% | $21.63 | $286,704 | +0.64% | |
2024-11-20 | Sale | MCENANY PATRICK J | Chairman of Board of Directors | 72,500 0.0612% | $21.29 | $1.54M | +3.88% | |
2024-11-20 | Sale | INGENITO GARY | Chief Med. & Reg. Officer | 38,000 0.032% | $21.20 | $805,562 | +3.88% | |
2024-11-19 | Sale | MCENANY PATRICK J | Chairman of Board of Directors | 98,345 0.0823% | $21.19 | $2.08M | +2.71% | |
2024-11-14 | Sale | MCENANY PATRICK J | Chairman of Board of Directors | 44,655 0.0376% | $21.75 | $971,336 | +1.24% | |
2024-11-13 | Sale | MCENANY PATRICK J | Chairman of Board of Directors | 92,500 0.0776% | $22.98 | $2.13M | -3.68% | |
2024-11-12 | Sale | MCENANY PATRICK J | Chairman of Board of Directors | 262,000 0.221% | $23.26 | $6.09M | -4.69% | |
2024-11-11 | Sale | MCENANY PATRICK J | Chairman of Board of Directors | 230,000 0.1936% | $23.55 | $5.42M | -6.33% | |
2024-08-21 | Sale | Tierney David S | director | 15,000 0.0124% | $20.10 | $301,455 | +4.93% | |
2024-08-20 | Sale | Miller Steve | Chief Op. & Scientific Officer | 150,000 0.1243% | $20.35 | $3.05M | +3.79% | |
2024-08-09 | Sale | INGENITO GARY | Chief Med. & Reg. Officer | 100,000 0.0826% | $18.04 | $1.8M | +16.13% | |
2024-08-09 | Sale | Del Carmen Jeffrey | Chief Commercial Officer | 36,058 0.0304% | $18.42 | $664,310 | +16.13% | |
2024-06-07 | Sale | Del Carmen Jeffrey | Chief Commercial Officer | 7,541 0.0066% | $16.07 | $121,184 | +33.61% |
MCENANY PATRICK J | Chairman of Board of Directors | 4478169 3.6873% | $93.46M | 36 | 14 | +56.08% |
Miller Steve | Chief Op. & Scientific Officer | 686996 0.5657% | $14.34M | 3 | 9 | +36.11% |
Tierney David S | director | 348874 0.2873% | $7.28M | 3 | 7 | +8.21% |
BIOMARIN PHARMACEUTICAL INC | 10 percent owner | 6666667 5.4892% | $139.13M | 1 | 0 | +100% |
HUCKEL HUBERT E MD | director | 1304134 1.0738% | $27.22M | 5 | 0 |
$193,151,375 | 134 | 8.18% | $2.71B | |
Catalyst Pharmaceuticals, Inc. (CPRX) | $11,588,217 | 69 | 42.07% | $2.53B |
$1,376,668 | 53 | 18.46% | $2.27B | |
$140,165,669 | 33 | 85.24% | $3.19B | |
$1,275,975,557 | 32 | 19.44% | $2.8B |
Increased Positions | 203 | +68.58% | 11M | +11.91% |
Decreased Positions | 126 | -42.57% | 9M | -9.16% |
New Positions | 61 | New | 3M | New |
Sold Out Positions | 36 | Sold Out | 2M | Sold Out |
Total Postitions | 373 | +26.01% | 98M | +2.75% |
Blackrock, Inc. | $444,641.00 | 16.05% | 19.43M | +407,638 | +2.14% | 2024-12-31 |
Vanguard Group Inc | $192,988.00 | 6.97% | 8.43M | +390,116 | +4.85% | 2024-12-31 |
State Street Corp | $132,683.00 | 4.79% | 5.8M | +111,230 | +1.96% | 2024-12-31 |
Deerfield Management Company, L.P. (Series C) | $71,715.00 | 2.59% | 3.13M | -3M | -49.71% | 2024-12-31 |
Dimensional Fund Advisors Lp | $68,968.00 | 2.49% | 3.01M | -5,757 | -0.19% | 2024-12-31 |
Pacer Advisors, Inc. | $67,652.00 | 2.44% | 2.96M | +151,495 | +5.4% | 2024-12-31 |
Goldman Sachs Group Inc | $64,146.00 | 2.32% | 2.8M | +1M | +90.35% | 2024-12-31 |
Renaissance Technologies Llc | $61,943.00 | 2.24% | 2.71M | +180,100 | +7.13% | 2024-12-31 |
Geode Capital Management, Llc | $61,013.00 | 2.2% | 2.67M | +1,048 | +0.04% | 2024-12-31 |
First Trust Advisors Lp | $51,132.00 | 1.85% | 2.23M | -195,139 | -8.03% | 2024-12-31 |